ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

10443	Companies
219247	Keywords
148701	Articles
115972	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 09/26/2025 at 07:00, 7 months 27 days ago

OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy
OSE Immunotherapeutics, Inserm Transfert, and Nantes University form a strategic partnership to advance immunotherapy for oncology, inflammation, and autoimmunity. The collaboration combines academic research and industrial expertise

Innovation Partnership Oncology Collaboration Immunotherapy
BRIEF

published on 09/24/2025 at 08:05, 7 months 29 days ago

OSE Immunotherapeutics Corrects Voting Rights Error Before General Meeting

Voting Rights Shareholder Meeting Accusations Material Error Proxy Firms
BRIEF

published on 09/24/2025 at 08:05, 7 months 29 days ago

OSE Immunotherapeutics corrige une erreur de droit de vote avant l'assemblée générale

Droit De Vote Assemblée Des Actionnaires Erreur Matérielle Accusations Sociétés De Procuration
PRESS RELEASE

published on 09/24/2025 at 08:00, 7 months 29 days ago

Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital
OSE Immunotherapeutics corrects material error in total number of shares and voting rights, refutes accusations, and provides clarity on shareholder agreements and proxy advisory recommendations

Correction Proxy Advisory Shareholder Agreements OSE Immunotherapeutics Material Error
BRIEF

published on 09/23/2025 at 22:35, 8 months ago

OSE Immunotherapeutics Responds to Court Decision

General Meeting Shareholder Rights OSE Immunotherapeutics Nantes Commercial Court Voting Rights Error
BRIEF

published on 09/23/2025 at 22:35, 8 months ago

OSE Immunotherapeutics répond à la décision du tribunal

Assemblée Générale Droits Des Actionnaires OSE Immunotherapeutics Tribunal De Commerce De Nantes Erreur Relative Aux Droits De Vote
PRESS RELEASE

published on 09/23/2025 at 22:30, 8 months ago

OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court regarding a shareholder action and prepares for the General Meeting on September 30, 2025, ensuring transparency and commitment

Transparency General Meeting OSE Immunotherapeutics Shareholder Action Nantes Commercial Court
PRESS RELEASE

published on 09/23/2025 at 22:30, 8 months ago

OSE Immunotherapeutics prend acte de la décision du Tribunal de commerce de Nantes
OSE Immunotherapeutics prend acte de la décision du Tribunal de commerce de Nantes rejetant ses demandes. Erreur matérielle identifiée dans le calcul des droits de vote. Préparation de l'Assemblée Générale le 30 septembre 2025

Biotechnologie Assemblée Générale Tribunal De Commerce OSE Immunotherapeutics Décision
BRIEF

published on 08/29/2025 at 08:05, 8 months 25 days ago

OSE Immunotherapeutics Clarifies Strategy Amid Shareholder Activism

Strategic Priorities Legal Proceedings OSE Immunotherapeutics Shareholder Activism Tedopi® And Lusvertikimab
BRIEF

published on 08/29/2025 at 08:05, 8 months 25 days ago

OSE Immunotherapeutics clarifie sa stratégie face à l'activisme des actionnaires

Priorités Stratégiques OSE Immunotherapeutics Activisme Des Actionnaires Procédures Judiciaires Tedopi® Et Lusvertikimab

Accesswire

Published on 05/23/2026 at 19:45, 7 hours 8 minutes ago

Golden Minerals Announces Closing of Equity Financing
Published on 05/23/2026 at 03:15, 23 hours 38 minutes ago

UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 23 hours 53 minutes ago

Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 1 day ago

Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 1 day ago

Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec

View all ACCESSWIRE

EQS Group

Published on 05/23/2026 at 16:30, 10 hours 22 minutes ago

HiFS 2026: Upgrading Four Major Digital Finance Solutions to Accelerate Financial Institutions Toward Agentic Banking
Published on 05/23/2026 at 15:57, 10 hours 56 minutes ago

EQS-Adhoc: Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
Published on 05/22/2026 at 22:05, 1 day 4 hours ago

Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Published on 05/22/2026 at 22:05, 1 day 4 hours ago

Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:51, 1 day 7 hours ago

Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices

Les Echos

Published on 05/22/2026 at 19:35, 1 day 7 hours ago

PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
Published on 05/22/2026 at 18:05, 1 day 8 hours ago

Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
Published on 05/22/2026 at 18:05, 1 day 8 hours ago

Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 1 day 14 hours ago

Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Published on 05/22/2026 at 12:52, 1 day 14 hours ago

Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026

View all LES ECHOS COMFI WIRE